Last reviewed · How we verify
2% povidone-iodine
2% povidone-iodine, developed by Mahidol University, is a marketed antiseptic with a well-established presence in the healthcare sector. The drug's key strength lies in its broad-spectrum antimicrobial activity, supported by a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent approaches expiration.
At a glance
| Generic name | 2% povidone-iodine |
|---|---|
| Also known as | PVP-I |
| Sponsor | Mahidol University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder (NA)
- CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee (NA)
- Pseudomonas Aeruginosa Injection Combined With Polyvinylpyrrolidone-Iodine in Immediate Breast Reconstruction Surgery With Implants (NA)
- Evaluation of Percutaneous Cryoneurotomy Compared to Surgical Open Neurotomy for the Management of Equinovarus Foot Deformity in Patients With Refractory Lower Limb Spasticity After Stroke (NA)
- The Efficacy of Wet Cupping Therapy on Cerebral Oxygenation (NA)
- Periodontal Granulation Tissue Preservation in Surgical Periodontitis Treatment (NA)
- Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2% povidone-iodine CI brief — competitive landscape report
- 2% povidone-iodine updates RSS · CI watch RSS
- Mahidol University portfolio CI